|
Malea
|
152 (88.9%)
|
74 (8.4%)
|
78 (88.6%)
|
0.914
|
|
Age (years)
|
45.2 ± 12.3
|
43.7 ± 12.7
|
46.6 ± 11.8
|
0.121
|
|
Cirrhosisa
|
139 (81.3%)
|
67 (80.7%)
|
72 (81.8%)
|
0.854
|
|
Time from onsetd to admission (days)b
|
20 (10–30)
|
16 (10–21)
|
20 (13–30)
|
0.083
|
|
MELD score
|
23.3 ± 4.7
|
22.8 ± 4.0
|
23.9 ± 5.2
|
0.132
|
|
Lg HBV DNA (IU/ml)
|
4.8 ± 1.9
|
4.9 ± 2.0
|
4.6 ± 1.8
|
0.383
|
|
HBV DNAa
|
|
Positive
|
150 (87.7%)
|
70 (84.3%)
|
80 (90.9%)
|
0.191
|
|
Negative
|
21 (12.3%)
|
13 (15.7%)
|
8 (9.1%)
|
0.191
|
|
HBeAga
|
|
Positive
|
90 (52.6%)
|
43 (51.8%)
|
47 (53.4%)
|
0.834
|
|
Negative
|
81 (47.4%)
|
40 (48.2%)
|
41 (46.6%)
|
0.834
|
|
HBsAgb
|
2582.0 (401.0–6012.0)
|
2582.0 (422.8–5884.0)
|
2613.0 (325.4–6197.3)
|
0.843
|
|
No medication with NAs when the disease onseta
|
127 (74.3%)
|
58 (69.9%)
|
69 (78.4%)
|
0.202
|
|
Never used before
|
89 (52.0%)
|
38 (45.8%)
|
51 (58.0%)
| |
|
Drug withdrawal
|
38 (22.2%)
|
20 (24.1%)
|
18 (20.5%)
| |
|
ADV
|
6 (3.5%)
|
2 (2.4%)
|
4 (4.5%)
| |
|
ETV
|
16 (9.4%)
|
12 (14.5%)
|
4 (4.5%)
| |
|
LAM
|
10 (5.8%)
|
4 (4.8%)
|
6 (6.8%)
| |
|
ETV+ADV
|
3 (1.8%)
|
1 (1.2%)
|
2 (2.3%)
| |
|
LAM+ADV
|
3 (1.8%)
|
1 (1.2%)
|
2 (2.3%)
| |
|
Medication with NAs when the disease onseta
|
44 (25.7%)
|
25 (30.1%)
|
19 (21.6%)
|
0.202
|
|
LAM
|
7 (4.1%)
|
4 (4.8%)
|
3 (3.4%)
| |
|
LAM+TDF
|
1 (0.6%)
|
1 (1.2%)
|
0
| |
|
LAM+ADV
|
7 (4.1%)
|
3 (3.6%)
|
4 (4.5%)
| |
|
ETV
|
26 (15.2%)
|
16 (19.3%)
|
10 (11.4%)
| |
|
ADV
|
2 (1.2%)
|
0
|
2 (2.3%)
| |
|
LdT
|
1 (0.6%)
|
1 (1.2%)
|
0
| |
|
NAs therapy after enrollmenta
|
171 (100%)
|
83 (100%)
|
88 (100%)
|
0.101
|
|
LAM
|
16 (9.4%)
|
6 (7.2%)
|
10 (11.4%)
| |
|
LAM+ADV
|
7 (4.1%)
|
5 (6.0%)
|
2 (2.3%)
| |
|
LAM+TDF
|
1 (0.6%)
|
1 (1.2%)
|
0
| |
|
ETV
|
142 (83.0%)
|
69 (83.1%)
|
73 (83.0%)
| |
|
ETV+ADV
|
2 (1.2%)
|
0
|
2 (2.3%)
| |
|
ADV
|
1 (0.6%)
|
0
|
1 (1.1%)
| |
|
LdT
|
2 (1.2%)
|
2 (2.4%)
|
0
| |
|
ALT (U/L)b
|
307.0 (117.2–573.6)
|
347.0 (131.7–685.9)
|
276.3 (106.8–514.1)
|
0.080
|
|
AST (U/L)b
|
214.0 (156.8–485.0)
|
291.3 (156.8–515.0)
|
184.4 (155.5–306.1)
|
0.054
|
|
Bilirubin (μmol/L)
|
353.9 ± 138.4
|
335.3 ± 133.8
|
371.4 ± 141.2
|
0.089
|
|
Albumin (g/L)
|
31.0 ± 4.1
|
31.4 ± 3.6
|
30.7 ± 4.5
|
0.257
|
|
Cholinesterase (IU/L)
|
3215.8 ± 1165.5
|
3262.0 ± 1063.3
|
3172.3 ± 1258.9
|
0.616
|
|
AFP (ng/ml)b
|
80.0 (33.1–180.0)
|
86.0 (45.5–240.0)
|
65.7 (21.7–132.8)
|
0.150
|
|
Cholesterol (mmol/L)
|
2.3 ± 0.8
|
2.4 ± 0.9
|
2.2 ± 0.7
|
0.059
|
|
Blood urea nitrogen (mmol/L) b
|
4.0 (3.2–6.1)
|
4.6 (3.1–6.1)
|
4.3 (3.5–6.3)
|
0.054
|
|
Creatinine (μmol/L)b
|
66.2 (56.8–81.0)
|
64.4 (55.4–76.6)
|
68.0 (58.1–84.5)
|
0.123
|
|
NH3 (μg/dl)
|
86.5 ± 45.2
|
89.2 ± 44.9
|
84.0 ± 45.7
|
0.449
|
|
Triglyceride (mmol/L)b
|
0.9 (0.6–1.5)
|
0.8 (0.5–1.7)
|
0.9 (0.6–1.4)
|
0.936
|
|
White blood cell (× 109/L)
|
7.3 ± 3.5
|
7.3 ± 3.4
|
7.3 ± 3.6
|
0.960
|
|
Lymphocyte percentage
|
20.7 ± 8.5
|
20.1 ± 8.1
|
21.3 ± 8.9
|
0.372
|
|
Monocyte percentage
|
9.5 ± 3.6
|
9.0 ± 3.5
|
9.8 ± 3.7
|
0.147
|
|
Lymphocyte/monocyte ratiob
|
2.2 (1.5–3.0)
|
2.2 (1.5–3.0)
|
2.1 (1.5–2.9)
|
0.502
|
|
Neutrophil percentage
|
68.6 ± 10.6
|
69.1 ± 9.6
|
68.1 ± .11.4
|
0.547
|
|
Procalcitonin (μg/L)b
|
0.6 (0.4–0.9)
|
0.6 (0.5–1.0)
|
0.6 (0.3–0.8)
|
0.197
|
|
PT (s)b
|
22.9 (20.2–27.9)
|
22.9 (19.2–22.8)
|
22.9 (20.7–27.6)
|
0.877
|
|
PTA (%)
|
35.9 ± 9.2
|
36.0 ± .10.3
|
35.8 ± 8.1
|
0.865
|
|
INRa
|
2.9 (1.7–2.3)
|
2.1 (1.6–2.6)
|
2.0 (1.7–2.2)
|
0.580
|
|
Red blood cell (× 1012/L)
|
3.9 ± 0.8
|
4.0 ± 0.8
|
3.8 ± 0.9
|
0.070
|
|
Hemoglobin (g/L)
|
124.2 ± 21.1
|
127.6 ± 18.9
|
121.5 ± 22.3
|
0.056
|
|
Platelet (×109/L)
|
105.2 ± 51.6
|
113.0 ± 45.3
|
97.9 ± 56.1
|
0.055
|
|
Ascitesa
|
103 (60.2%)
|
45 (54.2%)
|
58 (65.9%)
|
0.118
|
|
Infectionsa
|
92 (53.8%)
|
47 (56.6%)
|
45 (51.1%)
|
0.472
|
|
Electrolyte disturbancea
|
17 (9.9%)
|
5 (6.0%)
|
12 (13.6%)
|
0.096
|
|
Encephalopathya
|
21 (12.3%)
|
12 (14.5%)
|
9 (10.2%)
|
0.400
|
|
Hypoalbuminemiaa
|
35 (20.5%)
|
16 (19.3%)
|
19 (21.6%)
|
0.708
|
|
Hepatorenal syndromea
|
5 (2.9%)
|
1 (1.2%)
|
4 (4.5%)
|
0.369
|
|
Pleural effusiona
|
7 (4.1%)
|
3 (3.6%)
|
4 (4.5%)
|
1.000
|
|
Hyperthyroidisma
|
1 (0.6%)
|
1 (1.2%)
|
0
|
0.485
|
|
Peptic ulcera
|
2 (1.2%)
|
1 (1.2%)
|
1 (1.1%)
|
1.000
|
|
Artificial liver support after enrollmentc
|
–
|
87.98
|
84.13
|
0.582
|
|
Artificial centesis after enrollmentc
|
–
|
79.55
|
92.08
|
0.090
|
|
The time of antibiotic use after enrollmentc
|
–
|
91.72
|
80.60
|
0.141
|
